...
首页> 外文期刊>Current opinion in urology >Which injectable to use in the treatment of intrinsic sphincter deficiency?
【24h】

Which injectable to use in the treatment of intrinsic sphincter deficiency?

机译:哪种注射剂可用于治疗内在括约肌缺乏症?

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE OF REVIEW: Injectable agents are frequently used in the treatment of stress urinary incontinence in a variety of patients. Materials and techniques used in this therapy have evolved over time, with the relatively recent introduction of several novel therapies. The publication of recent evidence regarding these newer agents as well as older materials has provided fuel for the debate over which therapy is best. RECENT FINDINGS: Each of the agents discussed in this paper has variable biophysical properties that affect its efficacy and safety. Despite increasing evidence evaluating the various injectable materials for the treatment of stress incontinence, there is no clear data to establish any agent as superior or inferior in the various subgroups in which they are used. SUMMARY: The ideal periurethral injectable agent has not yet been identified though many of the currently used agents have acceptable efficacy in selected populations. There is active research into novel therapies that may prove effective.
机译:审查目的:注射剂常用于各种患者的压力性尿失禁的治疗。随着相对较新的几种新疗法的引入,该疗法中使用的材料和技术已经随着时间而发展。有关这些新型药物和较旧材料的最新证据的发表为有关哪种疗法最好的争论提供了动力。最近的发现:本文讨论的每种药物都有可变的生物物理特性,影响其功效和安全性。尽管评估用于治疗压力性尿失禁的各种可注射材料的证据越来越多,但尚无明确的数据来确定在使用它们的各个亚组中任何一种药物为优或劣。总结:尽管许多目前使用的药物在选定人群中具有可接受的疗效,但尚未确定理想的尿道周围注射剂。对于可能被证明有效的新型疗法有积极的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号